Spectral AI Announces 2023 Fourth Quarter and Full Year Financial Results

2023 Research & Development Revenue of $18.1 Million Expected to Increase to $28.0 Million in 2024 Commercialization Underway with Revenue Expected in 2H 2024 for DeepView AI®-Burn Indication in...

Related Keywords

United States ,Dallas ,Texas ,United Kingdom ,Conor Rodriguez ,J Michael Dimaio ,Deepak Sadagopan ,Paul Chadwick ,Devin Sullivan ,Peterm Carlson ,David Schull ,Erich Spangenberg ,Equity Group ,Administration For Strategic Preparedness ,Development Revenue ,Us Department Of Health ,Biomedical Advanced Research ,Spectral Ai Inc ,Research Development Revenue ,Product Development ,Drug Administration ,Human Services ,Development Authority ,Nasdaq ,Research Development ,Revenue Expected ,Burn Indication ,Additional Regulatory Submissions ,Diabetic Foot Ulcer Indications ,Chief Executive ,Driven Deepview ,Strategic Preparedness ,Eastern Time ,Investor Relations ,Registration Statement ,Stockholder Equity ,Consolidated Statements ,Months Ended ,Markets ,